<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nbsprot</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник войск РХБ защиты</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of NBC Protection Corps</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-5728</issn><issn pub-type="epub">3034-2791</issn><publisher><publisher-name>27 Научный центр</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35825/2587-5728-2025-9-2-118-150</article-id><article-id custom-type="edn" pub-id-type="custom">ehcise</article-id><article-id custom-type="elpub" pub-id-type="custom">nbsprot-405</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Биологическая безопасность и защита от биологических угроз</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Biological Security and Protection against Biological Threats</subject></subj-group></article-categories><title-group><article-title>Нерешенные и замалчиваемые научные проблемы,  оставленные пандемией COVID‐19</article-title><trans-title-group xml:lang="en"><trans-title>Unresolved and Suppressed Scientific Issues Left  by the COVID-19 Pandemic</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-3193-1032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Супотницкий</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Supotnitskiy</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Супотницкий Михаил Васильевич - Главный специалист, канд. биол. наук, ст. науч. сотр. </p><p> 111024,  г. Москва, проезд Энтузиастов, д. 19. </p></bio><bio xml:lang="en"><p> Mikhail V. Supotnitskiy - Senior Researcher. Cand. Sci. (Biol.). Chief Specialist.</p><p>Entuziastov Passage, 19, Moscow 111024</p><p>.</p></bio><email xlink:type="simple">27nc_l@mil.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «27 Научный центр имени академика Н.Д. Зелинского» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>27 Scientific Centre Named after Academician N.D. Zelinsky &#13;
of the Ministry of Defence of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>07</month><year>2025</year></pub-date><volume>9</volume><issue>2</issue><fpage>118</fpage><lpage>150</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Супотницкий М.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Супотницкий М.В.</copyright-holder><copyright-holder xml:lang="en">Supotnitskiy M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nbsprot.ru/jour/article/view/405">https://www.nbsprot.ru/jour/article/view/405</self-uri><abstract><sec><title>Основные моменты</title><p>Основные моменты</p><p>- противодействие пандемии COVID-19 в глобальном масштабе велось на основе сфальсифицированных представлений о вакцинах и сокрытии уже известных данных об иммунитете при коронавирусных инфекциях;</p><p>- глобальные меры против COVID-19, вопреки ожиданиям, часто применялись без учета известных иммунологических рисков, что требует пересмотра их стратегий для будущих пандемий;</p><p>- российская иммунология опасных инфекций, судя по публикациям ее лидеров, не извлекла для себя никаких уроков из ошибок, допущенных в ходе пандемии COVID-19. </p></sec><sec><title>Актуальность</title><p>Актуальность. Пандемия COVID‐19 обнажила научные проблемы в эпидемиологии и инфекционной иммунологии, о которых ранее либо не знали, либо, что еще хуже – знали, но замалчивали по причинам, далеким от науки.</p><p> Цель исследования – выявить нерешенные и замалчиваемые научные проблемы, оставленные пандемией COVID-19.</p><p> Источниковая база исследования. Обзорные и проблемные статьи в рецензируемых англоязычных научных журналах, доступные через глобальную сеть Интернет.</p></sec><sec><title> Метод исследования</title><p> Метод исследования. Аналитический. Использовались рекомендации Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Выявлено не менее 3 тыс. научных публикаций по особенностям эпидемического процесса, иммунологии болезни и осложнениям проводимой вакцинации. Из  них отобрано и проанализировано 116 обзорных статей.</p></sec><sec><title> Обсуждение</title><p> Обсуждение. Коронавирусные инфекции были хорошо изучены до пандемии COVID-19, однако в ходе глобальных мероприятий по ее ликвидации, накопленные ранее знания, не были использованы. Выявление механизмов развития эпидемии свелось к политическим обвинениям. Происхождение вируса осталось неизвестным. Вместо реальной иммунологии болезни врачам был навязан ее суррогат с фальсифицированной ролью антител. Иммунологические феномены, такие как антитело-зависимое усиление инфекции, патогенный прайминг, антигенный импринтинг, характерные для коронавирусных инфекций, замалчивались. Токсические и прионные свойства спайкового белка, использованного в качестве антигенного компонента, были скрыты от вакцинируемых векторными вакцинами на основе мРНК (Pfizer, Moderna и др.) и аденовирусов (OxfordAstraZeneca, Johnson &amp; Johnson и др.). По действующим документам регуляторных органов они являются препаратами для соматической генной терапии, а не вакцинами. Научно обоснованных противоэпидемических мероприятий для противодействия таким пандемиям разработано не было.</p></sec><sec><title> Заключение</title><p> Заключение. Произошла не только пандемическая катастрофа, но и, что более опасно, произошел катастрофический обвал накопленных научных знаний. Они не использовались и не будут соответствовать будущим пандемиям из-за зацикленности на вакцинации, ради обоснования которой шли на фальсификации и подлоги, нарушения законов и Конституции. Необходимо переосмысление ошибок, допущенных в ходе пандемии COVID-19, и формирование новой научной базы, которая могла бы быть использована для противодействия эпидемиям, пандемиям и биопреступлениям будущего.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Highlights</title><p>Highlights</p><p>- the global response to the COVID-19 pandemic was based on falsified assumptions about vaccines and the suppression of existing knowledge about immunity to coronavirus infections;</p><p>- global measures against COVID-19, contrary to expectations, were often implemented without accounting for known immunological risks, necessitating a revision of strategies for future pandemics;</p><p>- russian immunology of dangerous infections, judging by publications from its leading figures, has failed to learn any lessons from the mistakes made during the COVID-19 pandemic.</p></sec><sec><title> Relevance</title><p> Relevance. The COVID-19 pandemic exposed systemic flaws in infectious disease epidemiology and immunology – issues that were either previously unknown or, more troublingly, deliberately suppressed for non-scientific reasons.</p><p> Purpose of the study is to identify unresolved and suppressed scientific issues left by the COVID-19 pandemic.</p></sec><sec><title> Study base sources</title><p> Study base sources. Review and problem-focused articles in peer-reviewed English-language scientific journals, accessible via the Internet.</p></sec><sec><title> Method</title><p> Method. Analytical. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Over 3,000 scientific publications on the features of the epidemic process, disease immunology, and vaccination complications were identified. Of these, 114 review articles were selected and analyzed.</p></sec><sec><title> Discussion</title><p> Discussion. Coronavirus infections were well-studied prior to the COVID-19 pandemic. However, during global efforts to combat it, previously accumulated knowledge was disregarded. The investigation into the mechanisms of the epidemic was reduced to political blame-shifting. The origin of the virus remains unknown. Instead of genuine disease immunology, physicians were presented with a surrogate model that falsified the role of antibodies. Immunological phenomena characteristic of coronavirus infections–such as antibody-dependent enhancement (ADE), pathogenic priming, and antigenic imprinting–were deliberately ignored. The toxic and prion-like properties of the spike protein, used as the antigenic component in vector-based mRNA vaccines (Pfizer, Moderna, etc.) and adenoviral vaccines (Oxford–AstraZeneca, Johnson &amp; Johnson, etc.), were concealed from recipients. Under current regulatory frameworks, these products are classified as somatic gene therapy drugs, not vaccines. No scientifically grounded public health measures were developed in advance to counter the pandemic.</p></sec><sec><title> Conclusions</title><p> Conclusions. The pandemic was not only a public health catastrophe but also–more dangerously–a catastrophic collapse of the scientific knowledge applied. This knowledge failed to align with the realities of COVID-19 and will remain inadequate for future pandemics due to an obsessive focus on vaccination, which was justified through falsification, fraud, and violations of laws and constitutional principles. A critical reassessment of the mistakes made during the COVID-19 pandemic is essential, along with the development of a new scientific foundation to address future pandemics and biocrimes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>антигенный импринтинг</kwd><kwd>антитело</kwd><kwd>антитело-зависимое усиление инфекции</kwd><kwd>биопреступление</kwd><kwd>патогенный прайминг</kwd><kwd>векторная вакцина</kwd><kwd>мРНК-вакцина</kwd><kwd>прионоподобный белок</kwd><kwd>спайковый белок</kwd><kwd>фальсифиция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>antigenic imprinting</kwd><kwd>antibody</kwd><kwd>antibody-dependent enhancement (ADE)</kwd><kwd>biocrime</kwd><kwd>falsification</kwd><kwd>pathogenic priming</kwd><kwd>prion-like protein</kwd><kwd>spike protein</kwd><kwd>vector vaccine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ghai RR, Carpenter A, Liew AY, Martin KB, Herring MK, Gerber SI, et al. Animal Reservoirs and Hosts for Emerging Alphacoronaviruses and Betacoronaviruses. Emerg Infect Dis. 2021;27(4):1015–22. https://doi.org/10.3201/eid2704.203945</mixed-citation><mixed-citation xml:lang="en">Ghai RR, Carpenter A, Liew AY, Martin KB, Herring MK, Gerber SI, et al. Animal Reservoirs and Hosts for Emerging Alphacoronaviruses and Betacoronaviruses. Emerg Infect Dis. 2021;27(4):1015–22. https://doi.org/10.3201/eid2704.203945</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260. https://doi.org/10.1016/j.meegid.2020.104260</mixed-citation><mixed-citation xml:lang="en">Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260. https://doi.org/10.1016/j.meegid.2020.104260</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Basavaraju SV, Patton ME, Grimm K, Rasheed MAU, Lester S, Mills L, et al. Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reactive Antibodies: December 2019–January 2020. Clin Infect Dis. 2021;72(12):e1004-9. https://doi.org/10.1093/cid/ciaa1785</mixed-citation><mixed-citation xml:lang="en">Basavaraju SV, Patton ME, Grimm K, Rasheed MAU, Lester S, Mills L, et al. Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reactive Antibodies: December 2019–January 2020. Clin Infect Dis. 2021;72(12):e1004-9. https://doi.org/10.1093/cid/ciaa1785</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lecis R, Mucedda M, Pidinchedda E, Pittau M, Alberti A. Correction to: Molecular identification of Betacoronavirus in bats from Sardinia (Italy): first detection and phylogeny. Virus Genes. 2021;57(5):474. https://doi.org/10.1007/s11262-021-01856-7</mixed-citation><mixed-citation xml:lang="en">Lecis R, Mucedda M, Pidinchedda E, Pittau M, Alberti A. Correction to: Molecular identification of Betacoronavirus in bats from Sardinia (Italy): first detection and phylogeny. Virus Genes. 2021;57(5):474. https://doi.org/10.1007/s11262-021-01856-7</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Blangiardo M, Cameletti M, Pirani M, Corsetti G, Battaglini M, Baio G. Estimating weekly excess mortality at sub-national level in Italy during the COVID-19 pandemic. PLoS One. 2020;15(10):e0240286. https://doi.org/10.1371/journal.pone.0240286</mixed-citation><mixed-citation xml:lang="en">Blangiardo M, Cameletti M, Pirani M, Corsetti G, Battaglini M, Baio G. Estimating weekly excess mortality at sub-national level in Italy during the COVID-19 pandemic. PLoS One. 2020;15(10):e0240286. https://doi.org/10.1371/journal.pone.0240286</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3(1):237–61. https://doi.org/10.1146/annurev-virology-110615-042301</mixed-citation><mixed-citation xml:lang="en">Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3(1):237–61. https://doi.org/10.1146/annurev-virology-110615-042301</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J Neuroimmune Pharmacol. 2020;15(3):359-86. https://doi.org/10.1007/s11481-020-09944-5</mixed-citation><mixed-citation xml:lang="en">Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J Neuroimmune Pharmacol. 2020;15(3):359-86. https://doi.org/10.1007/s11481-020-09944-5</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S et al. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells. 2021;10(4):821. https://doi.org/10.3390/cells10040821</mixed-citation><mixed-citation xml:lang="en">Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S et al. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells. 2021;10(4):821. https://doi.org/10.3390/cells10040821</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. Mol Pharmacol. 2020;97(5):351-53. https://doi.org/10.1124/molpharm.120.000014</mixed-citation><mixed-citation xml:lang="en">Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. Mol Pharmacol. 2020;97(5):351-53. https://doi.org/10.1124/molpharm.120.000014</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. Virology. 2006;350(2):358-69. https://doi.org/10.1016/j.virol.2006.02.003</mixed-citation><mixed-citation xml:lang="en">Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. Virology. 2006;350(2):358-69. https://doi.org/10.1016/j.virol.2006.02.003</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Guruprasad L. Human coronavirus spike protein-host receptor recognition. Prog Biophys Mol Biol. 2021;161:39-53. https://doi.org/10.1016/j.pbiomolbio.2020.10.006</mixed-citation><mixed-citation xml:lang="en">Guruprasad L. Human coronavirus spike protein-host receptor recognition. Prog Biophys Mol Biol. 2021;161:39-53. https://doi.org/10.1016/j.pbiomolbio.2020.10.006</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020;7:157. https://doi.org/10.3389/fmolb.2020.00157</mixed-citation><mixed-citation xml:lang="en">Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020;7:157. https://doi.org/10.3389/fmolb.2020.00157</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sattar S, Kabat J, Jerome K, Feldmann F, Bailey K, Mehedi M. Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2. Front Microbiol. 2023;14:1073789. https://doi.org/10.3389/fmicb.2023.1073789</mixed-citation><mixed-citation xml:lang="en">Sattar S, Kabat J, Jerome K, Feldmann F, Bailey K, Mehedi M. Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2. Front Microbiol. 2023;14:1073789. https://doi.org/10.3389/fmicb.2023.1073789</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Igyártó BZ, Qin Z. The mRNA-LNP vaccines – the good, the bad and the ugly? Front Immunol. 2024;15:1336906. https://doi.org/10.3389/fimmu.2024.1336906</mixed-citation><mixed-citation xml:lang="en">Igyártó BZ, Qin Z. The mRNA-LNP vaccines – the good, the bad and the ugly? Front Immunol. 2024;15:1336906. https://doi.org/10.3389/fimmu.2024.1336906</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tetz G, Tetz V. Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2. Microorganisms. 2022;10(2):280. https://doi.org/10.3390/microorganisms10020280</mixed-citation><mixed-citation xml:lang="en">Tetz G, Tetz V. Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2. Microorganisms. 2022;10(2):280. https://doi.org/10.3390/microorganisms10020280</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Seneff S, Kyriakopoulos AM, Nigh G, McCullough PA. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. Cureus. 2023;15(2):e34872. https://doi.org/10.7759/cureus.34872</mixed-citation><mixed-citation xml:lang="en">Seneff S, Kyriakopoulos AM, Nigh G, McCullough PA. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. Cureus. 2023;15(2):e34872. https://doi.org/10.7759/cureus.34872</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Perez JCP, Chalmin CM, Montagnier L. Towards the emergence of a new form of the neurodegenerative Creutzfeldt-Jakob disease: Twenty six cases of CJD declared a few days after a COVID-19 vaccine Jab. International Journal of Vaccine Theory, Practice, and Research. 2023;3(1):727-53. URL:https://www.researchgate.net/publication/367167725 (дата обращения: 21.01.2025).</mixed-citation><mixed-citation xml:lang="en">Perez JCP, Chalmin CM, Montagnier L. Towards the emergence of a new form of the neurodegenerative Creutzfeldt-Jakob disease: Twenty six cases of CJD declared a few days after a COVID-19 vaccine Jab. International Journal of Vaccine Theory, Practice, and Research. 2023;3(1):727-53. URL:https://www.researchgate.net/publication/367167725 (дата обращения: 21.01.2025).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. Int J Mol Sci. 2020;21(16):5807. https://doi.org/10.3390/ijms21165807</mixed-citation><mixed-citation xml:lang="en">Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. Int J Mol Sci. 2020;21(16):5807. https://doi.org/10.3390/ijms21165807</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658-63. https://doi.org/10.1016/j.toxrep.2020.04.012</mixed-citation><mixed-citation xml:lang="en">Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658-63. https://doi.org/10.1016/j.toxrep.2020.04.012</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kopańska M, Batoryna M, Bartman P, Szczygielski J, Banaś-Ząbczyk A. Disorders of the Cholinergic System in COVID-19 Era–A Review of the Latest Research. Int J Mol Sci. 2022;23(2):672. https://doi.org/10.3390/ijms23020672</mixed-citation><mixed-citation xml:lang="en">Kopańska M, Batoryna M, Bartman P, Szczygielski J, Banaś-Ząbczyk A. Disorders of the Cholinergic System in COVID-19 Era–A Review of the Latest Research. Int J Mol Sci. 2022;23(2):672. https://doi.org/10.3390/ijms23020672</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2012;65(1):1-46. https://doi.org/10.1124/pr.112.006809</mixed-citation><mixed-citation xml:lang="en">Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2012;65(1):1-46. https://doi.org/10.1124/pr.112.006809</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Лурия С, Дарнелл Дж. Общая вирусология. М.: Изд. «Мир»; 1970. Luria SE, Darnell JE. [General Virology]. Moscow: Mir; 1970 (In Russian).</mixed-citation><mixed-citation xml:lang="en">Лурия С, Дарнелл Дж. Общая вирусология. М.: Изд. «Мир»; 1970. Luria SE, Darnell JE. [General Virology]. Moscow: Mir; 1970 (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs. 2010;2(1):53-66. https://doi.org/4161/mabs.2.1.10788</mixed-citation><mixed-citation xml:lang="en">Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs. 2010;2(1):53-66. https://doi.org/4161/mabs.2.1.10788</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bong YS, Brown D, Chung E, Ananthaswamy N, Chen R, Lewoczko E, et al. S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Front Immunol. 2025;15:1495561. https://doi.org/10.3389/fimmu.2024.1495561</mixed-citation><mixed-citation xml:lang="en">Bong YS, Brown D, Chung E, Ananthaswamy N, Chen R, Lewoczko E, et al. S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Front Immunol. 2025;15:1495561. https://doi.org/10.3389/fimmu.2024.1495561</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hemida MG, Alnaeem A, Chu DK, Perera RA, Chan SM, Almathen F, et al. Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015. Emerg Microbes Infect. 2017;6(6):e56. https://doi.org/10.1038/emi.2017.44</mixed-citation><mixed-citation xml:lang="en">Hemida MG, Alnaeem A, Chu DK, Perera RA, Chan SM, Almathen F, et al. Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015. Emerg Microbes Infect. 2017;6(6):e56. https://doi.org/10.1038/emi.2017.44</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bachmann MF, Mohsen MO, Zha L, Vogel M, Speiser DE. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines. 2021;6(1):2. https://doi.org/10.1038/s41541-020-00264-6</mixed-citation><mixed-citation xml:lang="en">Bachmann MF, Mohsen MO, Zha L, Vogel M, Speiser DE. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines. 2021;6(1):2. https://doi.org/10.1038/s41541-020-00264-6</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Dintzis HM, Dintzis RZ, Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A. 1976;73(10):3671-5. https://doi.org/10.1073/pnas.73.10.3671</mixed-citation><mixed-citation xml:lang="en">Dintzis HM, Dintzis RZ, Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A. 1976;73(10):3671-5. https://doi.org/10.1073/pnas.73.10.3671</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235-70. https://doi.org/10.1146/annurev.immunol.15.1.235</mixed-citation><mixed-citation xml:lang="en">Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235-70. https://doi.org/10.1146/annurev.immunol.15.1.235</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Bachmann MF, Mohsen MO, Zha L, Vogel M, Speiser DE. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines. 2021;6(1):2. https://doi.org/10.1038/s41541-020-00264-6</mixed-citation><mixed-citation xml:lang="en">Bachmann MF, Mohsen MO, Zha L, Vogel M, Speiser DE. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines. 2021;6(1):2. https://doi.org/10.1038/s41541-020-00264-6</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003;13(6):387-98. https://doi.org/10.1002/rmv.405</mixed-citation><mixed-citation xml:lang="en">Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003;13(6):387-98. https://doi.org/10.1002/rmv.405</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46-61. https://doi.org/10.1038/nri.2017.106</mixed-citation><mixed-citation xml:lang="en">Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46-61. https://doi.org/10.1038/nri.2017.106</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci. 1964;42:465-82. https://doi.org/10.1038/icb.1964.44</mixed-citation><mixed-citation xml:lang="en">Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci. 1964;42:465-82. https://doi.org/10.1038/icb.1964.44</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246-251. https://doi.org/10.1016/j.jhin.2020.01.022</mixed-citation><mixed-citation xml:lang="en">Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246-251. https://doi.org/10.1016/j.jhin.2020.01.022</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Shitrit P, Zuckerman NS, Mor O, Gottesman BS, Chowers M. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. Euro Surveill. 2021;26(39):2100822. https://doi.org/10.2807/1560-7917.es.2021.26.39.2100822</mixed-citation><mixed-citation xml:lang="en">Shitrit P, Zuckerman NS, Mor O, Gottesman BS, Chowers M. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. Euro Surveill. 2021;26(39):2100822. https://doi.org/10.2807/1560-7917.es.2021.26.39.2100822</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Vennema H, de Groot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol. 1990;64(3):1407-9. https://doi.org/10.1128/JVI.64.3.1407-1409.1990</mixed-citation><mixed-citation xml:lang="en">Vennema H, de Groot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol. 1990;64(3):1407-9. https://doi.org/10.1128/JVI.64.3.1407-1409.1990</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Klepfer S, Reed AP, Martinez M, Bhogal B, Jones E, Miller TJ. Cloning and expression of FECV spike gene in vaccinia virus. Immunization with FECV S causes early death after FIPV challenge. Adv Exp Med Biol. 1995;380:235-41. https://doi.org/10.1007/978-1-4615-1899-0_38</mixed-citation><mixed-citation xml:lang="en">Klepfer S, Reed AP, Martinez M, Bhogal B, Jones E, Miller TJ. Cloning and expression of FECV spike gene in vaccinia virus. Immunization with FECV S causes early death after FIPV challenge. Adv Exp Med Biol. 1995;380:235-41. https://doi.org/10.1007/978-1-4615-1899-0_38</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. Infect Dis Ther. 2020;9(2):255-74. https://doi.org/10.1007/s40121-020-00371-w</mixed-citation><mixed-citation xml:lang="en">Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. Infect Dis Ther. 2020;9(2):255-74. https://doi.org/10.1007/s40121-020-00371-w</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Li L, Wo J, Shao J, Zhu H, Wu N, Li M, et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. J Clin Virol. 2003;28(3):239-44. https://doi.org/10.1016/S1386-6532(03)00195-1</mixed-citation><mixed-citation xml:lang="en">Li L, Wo J, Shao J, Zhu H, Wu N, Li M, et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. J Clin Virol. 2003;28(3):239-44. https://doi.org/10.1016/S1386-6532(03)00195-1</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Gaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J Virol. 2011;85(20):10582-97. https://doi.org/doi:10.1128/JVI.00671-11</mixed-citation><mixed-citation xml:lang="en">Gaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J Virol. 2011;85(20):10582-97. https://doi.org/doi:10.1128/JVI.00671-11</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208-14. https://doi.org/10.1016/j.bbrc.2014.07.090</mixed-citation><mixed-citation xml:lang="en">Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208-14. https://doi.org/10.1016/j.bbrc.2014.07.090</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Houser KV, Broadbent AJ, Gretebeck L, Vogel L, Lamirande EW, Sutton T, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 2017;13(8):e1006565. https://doi.org/10.1371/journal.ppat.1006565</mixed-citation><mixed-citation xml:lang="en">Houser KV, Broadbent AJ, Gretebeck L, Vogel L, Lamirande EW, Sutton T, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 2017;13(8):e1006565. https://doi.org/10.1371/journal.ppat.1006565</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Clay C, Donart N, Fomukong N, Knight JB, Lei W, Price L, et al. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol. 2012;86(8):4234-44. https://doi.org/10.1128/JVI.06791-11</mixed-citation><mixed-citation xml:lang="en">Clay C, Donart N, Fomukong N, Knight JB, Lei W, Price L, et al. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol. 2012;86(8):4234-44. https://doi.org/10.1128/JVI.06791-11</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2011;17(2):195-9. https://doi.org/10.1038/nm.2262</mixed-citation><mixed-citation xml:lang="en">Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2011;17(2):195-9. https://doi.org/10.1038/nm.2262</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18(3):541-55. https://doi.org/10.1128/CMR.18.3.541-555.2005</mixed-citation><mixed-citation xml:lang="en">Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18(3):541-55. https://doi.org/10.1128/CMR.18.3.541-555.2005</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Shimizu J, Sasaki T, Koketsu R, Morita R, Yoshimura Y, Murakami A, et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci Rep. 2022;12(1):15612. https://doi.org/10.1038/s41598-022-19993-w</mixed-citation><mixed-citation xml:lang="en">Shimizu J, Sasaki T, Koketsu R, Morita R, Yoshimura Y, Murakami A, et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci Rep. 2022;12(1):15612. https://doi.org/10.1038/s41598-022-19993-w</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Yahi N, Chahinian H, Fantini J. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? J Infect. 2021;83(5):607-35. https://doi.org/10.1016/j.jinf.2021.08.010</mixed-citation><mixed-citation xml:lang="en">Yahi N, Chahinian H, Fantini J. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? J Infect. 2021;83(5):607-35. https://doi.org/10.1016/j.jinf.2021.08.010</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas S, Smatti MK, Ouhtit A, Cyprian FS, Almaslamani MA, Thani AA, et al. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis. Mol Immunol. 2022;152:172-82. https://doi.org/10.1016/j.molimm.2022.11.010</mixed-citation><mixed-citation xml:lang="en">Thomas S, Smatti MK, Ouhtit A, Cyprian FS, Almaslamani MA, Thani AA, et al. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis. Mol Immunol. 2022;152:172-82. https://doi.org/10.1016/j.molimm.2022.11.010</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Deng T, Zhang Y, Niu W, Nie Q, Yang S, et al. ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection. iScience. 2022;25(1):103720. https://doi.org/10.1016/j.isci.2021.103720</mixed-citation><mixed-citation xml:lang="en">Wang Z, Deng T, Zhang Y, Niu W, Nie Q, Yang S, et al. ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection. iScience. 2022;25(1):103720. https://doi.org/10.1016/j.isci.2021.103720</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses. J Immunol. 2019;202(2):335-40. https://doi.org/10.4049/jimmunol.1801149</mixed-citation><mixed-citation xml:lang="en">Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses. J Immunol. 2019;202(2):335-40. https://doi.org/10.4049/jimmunol.1801149</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Brown EL, Essigmann HT. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19. mSphere. 2021;6(2):e00056-21. https://doi.org/10.1128/mSphere.00056-21</mixed-citation><mixed-citation xml:lang="en">Brown EL, Essigmann HT. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19. mSphere. 2021;6(2):e00056-21. https://doi.org/10.1128/mSphere.00056-21</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Francis TJr. Influenza: the new acquayantance. Ann Intern Med. 1953;39(2):203-21. https://doi.org/10.7326/0003-4819-39-2-203</mixed-citation><mixed-citation xml:lang="en">Francis TJr. Influenza: the new acquayantance. Ann Intern Med. 1953;39(2):203-21. https://doi.org/10.7326/0003-4819-39-2-203</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza. J Theor Biol. 2011;288:29-34. https://doi.org/10.1016/j.jtbi.2011.08.003</mixed-citation><mixed-citation xml:lang="en">Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza. J Theor Biol. 2011;288:29-34. https://doi.org/10.1016/j.jtbi.2011.08.003</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Forresi J, Edeling MA. Immune imprinting of SARS-CoV-2 responses: changing first immune impressions. mSphere. 2024;9(4):e0075823. https://doi.org/10.1128/msphere.00758-23</mixed-citation><mixed-citation xml:lang="en">Forresi J, Edeling MA. Immune imprinting of SARS-CoV-2 responses: changing first immune impressions. mSphere. 2024;9(4):e0075823. https://doi.org/10.1128/msphere.00758-23</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020;3:100051. https://doi.org/10.1016/j.jtauto.2020.100051</mixed-citation><mixed-citation xml:lang="en">Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020;3:100051. https://doi.org/10.1016/j.jtauto.2020.100051</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021;11:617089. https://doi.org/10.3389/fimmu.2020.617089</mixed-citation><mixed-citation xml:lang="en">Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021;11:617089. https://doi.org/10.3389/fimmu.2020.617089</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, et al. «Spikeopathy»: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines. 2023;11(8):2287. https://doi.org/10.3390/biomedicines11082287</mixed-citation><mixed-citation xml:lang="en">Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, et al. «Spikeopathy»: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines. 2023;11(8):2287. https://doi.org/10.3390/biomedicines11082287</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, et al. The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines. 2015;14(2):235-51. https://doi.org/10.1586/14760584.2015.957685</mixed-citation><mixed-citation xml:lang="en">Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, et al. The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines. 2015;14(2):235-51. https://doi.org/10.1586/14760584.2015.957685</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1-2):148-58. https://doi.org/10.1016/j.ymgme.2003.08.016</mixed-citation><mixed-citation xml:lang="en">Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1-2):148-58. https://doi.org/10.1016/j.ymgme.2003.08.016</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, et al. Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics. 2022;14(12):2682. https://doi.org/10.3390/pharmaceutics14122682</mixed-citation><mixed-citation xml:lang="en">Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, et al. Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics. 2022;14(12):2682. https://doi.org/10.3390/pharmaceutics14122682</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318-24. https://doi.org/10.1038/d41586-021-02483-w</mixed-citation><mixed-citation xml:lang="en">Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318-24. https://doi.org/10.1038/d41586-021-02483-w</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Sparmann A, Vogel J. RNA-based medicine: from molecular mechanisms to therapy. EMBO J. 2023;42(21):e114760. https://doi.org/10.15252/embj.2023114760</mixed-citation><mixed-citation xml:lang="en">Sparmann A, Vogel J. RNA-based medicine: from molecular mechanisms to therapy. EMBO J. 2023;42(21):e114760. https://doi.org/10.15252/embj.2023114760</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles–From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11):16982-17015. https://doi.org/10.1021/acsnano.1c04996</mixed-citation><mixed-citation xml:lang="en">Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles–From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11):16982-17015. https://doi.org/10.1021/acsnano.1c04996</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Nuovo GJ, Magro C, Shaffer T, Awad H, Suster D, Mikhail S, et al. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann Diagn Pathol. 2021;51:151682. https://doi.org/10.1016/j.anndiagpath.2020.151682</mixed-citation><mixed-citation xml:lang="en">Nuovo GJ, Magro C, Shaffer T, Awad H, Suster D, Mikhail S, et al. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann Diagn Pathol. 2021;51:151682. https://doi.org/10.1016/j.anndiagpath.2020.151682</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Olszewska B, Zaryczańska A, Nowicki RJ, Sokołowska-Wojdyło M. Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review. Front Med (Lausanne). 2024;11:1325478. https://doi.org/10.3389/fmed.2024.1325478</mixed-citation><mixed-citation xml:lang="en">Olszewska B, Zaryczańska A, Nowicki RJ, Sokołowska-Wojdyło M. Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review. Front Med (Lausanne). 2024;11:1325478. https://doi.org/10.3389/fmed.2024.1325478</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Hanna N, Heffes-Doon A, Lin X, Manzano De Mejia C, Botros B, Gurzenda E, et al. Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk. JAMA Pediatr. 2022;176(12):1268-70. https://doi.org/10.1001/jamapediatrics.2022.3581</mixed-citation><mixed-citation xml:lang="en">Hanna N, Heffes-Doon A, Lin X, Manzano De Mejia C, Botros B, Gurzenda E, et al. Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk. JAMA Pediatr. 2022;176(12):1268-70. https://doi.org/10.1001/jamapediatrics.2022.3581</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Lin X, Botros B, Hanna M, Gurzenda E, De Mejia CM, Chavez M, et al. Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination. Am J Obstet Gynecol. 2024;230(6):e113-e116.22. https://doi.org/10.1016/j.ajog.2024.01.022</mixed-citation><mixed-citation xml:lang="en">Lin X, Botros B, Hanna M, Gurzenda E, De Mejia CM, Chavez M, et al. Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination. Am J Obstet Gynecol. 2024;230(6):e113-e116.22. https://doi.org/10.1016/j.ajog.2024.01.022</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol. 2008;82(23):11705-13. https://doi.org/10.1128/JVI.01320-08</mixed-citation><mixed-citation xml:lang="en">Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol. 2008;82(23):11705-13. https://doi.org/10.1128/JVI.01320-08</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Brogna C, Cristoni S, Marino G, Montano L, Viduto V, Fabrowski M, et al. Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms. Proteomics Clin Appl. 2023;17(6):e2300048. https://doi.org/10.1002/prca.202300048</mixed-citation><mixed-citation xml:lang="en">Brogna C, Cristoni S, Marino G, Montano L, Viduto V, Fabrowski M, et al. Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms. Proteomics Clin Appl. 2023;17(6):e2300048. https://doi.org/10.1002/prca.202300048</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Castruita JAS, Schneider UV, Mollerup S, Leineweber TD, Weis N, Bukh J, et al. SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination. APMIS. 2023;131(3):128-32. https://doi.org/10.1111/apm.13294</mixed-citation><mixed-citation xml:lang="en">Castruita JAS, Schneider UV, Mollerup S, Leineweber TD, Weis N, Bukh J, et al. SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination. APMIS. 2023;131(3):128-32. https://doi.org/10.1111/apm.13294</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Thorp JA, Benavides A, Thorp MM, Biss K, Threet J, Mccullough P. Are COVID-19 Vaccines in Pregnancy as Safe and Effective as the Medical Industrial Complex Claim? Part I. Science, Public Health Policy, and the Law. 2025;6:2019-25. URL:https://publichealthpolicyjournal.com/are-covid-19-vaccines-in-pregnancy-as-safe-and-effective-as-the-medical-industrial-complex-claim-part-i/ (дата обращения: 13.02.2025).</mixed-citation><mixed-citation xml:lang="en">Thorp JA, Benavides A, Thorp MM, Biss K, Threet J, Mccullough P. Are COVID-19 Vaccines in Pregnancy as Safe and Effective as the Medical Industrial Complex Claim? Part I. Science, Public Health Policy, and the Law. 2025;6:2019-25. URL:https://publichealthpolicyjournal.com/are-covid-19-vaccines-in-pregnancy-as-safe-and-effective-as-the-medical-industrial-complex-claim-part-i/ (дата обращения: 13.02.2025).</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Супотницкий МВ. Опасность мРНК-технологий. Вестник войск РХБ защиты. 2024;8(3):205-31. EDN:ifdujf. https://doi.org/10.35825/2587-5728-2024-8-3-205-231</mixed-citation><mixed-citation xml:lang="en">Supotnitskiy MV. [mRNA Technologies Danger]. Vestnik voysk RKhB zashchity. 2024;8(3):205-31. (In Russian). English version: Supotnitskiy MV. mRNA Technologies Danger. Journal of NBC Protection Corps. 2024;8(3):205-31. https://doi.org/10.35825/2587-5728-2024-8-3-205-2310</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Pardridge WM. A Historical Review of Brain Drug Delivery. Pharmaceutics. 2022;14(6):1283. https://doi.org/10.3390/pharmaceutics14061283</mixed-citation><mixed-citation xml:lang="en">Pardridge WM. A Historical Review of Brain Drug Delivery. Pharmaceutics. 2022;14(6):1283. https://doi.org/10.3390/pharmaceutics14061283</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7(7):e40385. https://doi.org/10.1371/journal.pone.0040385</mixed-citation><mixed-citation xml:lang="en">Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7(7):e40385. https://doi.org/10.1371/journal.pone.0040385</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654-63. https://doi.org/10.1128/jvi.02696-06</mixed-citation><mixed-citation xml:lang="en">Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654-63. https://doi.org/10.1128/jvi.02696-06</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Sallard E, Zhang W, Aydin M, Schröer K, Ehrhardt A. The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine. Viruses. 2023;15(1):204. https://doi.org/10.3390/v15010204</mixed-citation><mixed-citation xml:lang="en">Sallard E, Zhang W, Aydin M, Schröer K, Ehrhardt A. The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine. Viruses. 2023;15(1):204. https://doi.org/10.3390/v15010204</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91. https://doi.org/10.1038/s41541-020-00243-x</mixed-citation><mixed-citation xml:lang="en">Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91. https://doi.org/10.1038/s41541-020-00243-x</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Byrnes AP, Rusby JE, Wood MJ, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience. 1995;66(4):1015-24. https://doi.org/10.1016/0306-4522(95)00068-t</mixed-citation><mixed-citation xml:lang="en">Byrnes AP, Rusby JE, Wood MJ, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience. 1995;66(4):1015-24. https://doi.org/10.1016/0306-4522(95)00068-t</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Lawrence MS, Foellmer HG, Elsworth JD, Kim JH, Leranth C, Kozlowski DA, et al. Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus. Gene Ther. 1999;6(8):1368-79. https://doi.org/10.1038/sj.gt.3300958</mixed-citation><mixed-citation xml:lang="en">Lawrence MS, Foellmer HG, Elsworth JD, Kim JH, Leranth C, Kozlowski DA, et al. Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus. Gene Ther. 1999;6(8):1368-79. https://doi.org/10.1038/sj.gt.3300958</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Müller T, Pring-Akerblom P, et al. Complement activation by recombinant adenoviruses. Gene Ther. 2001;8(23):1794-800. https://doi.org/10.1038/sj.gt.3301611</mixed-citation><mixed-citation xml:lang="en">Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Müller T, Pring-Akerblom P, et al. Complement activation by recombinant adenoviruses. Gene Ther. 2001;8(23):1794-800. https://doi.org/10.1038/sj.gt.3301611</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005;12(5):427-36. https://doi.org/10.1038/sj.gt.3302347</mixed-citation><mixed-citation xml:lang="en">Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005;12(5):427-36. https://doi.org/10.1038/sj.gt.3302347</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni S, Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol. 2007;81(9):4866-71. https://doi.org/10.1128/JVI.02819-06</mixed-citation><mixed-citation xml:lang="en">Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni S, Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol. 2007;81(9):4866-71. https://doi.org/10.1128/JVI.02819-06</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Mörz M. A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19. Vaccines (Basel). 2022;10(10):1651. https://doi.org/10.3390/vaccines10101651</mixed-citation><mixed-citation xml:lang="en">Mörz M. A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19. Vaccines (Basel). 2022;10(10):1651. https://doi.org/10.3390/vaccines10101651</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. 2022;32(5):249-56. https://doi.org/10.1016/j.tcm.2022.02.008</mixed-citation><mixed-citation xml:lang="en">Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. 2022;32(5):249-56. https://doi.org/10.1016/j.tcm.2022.02.008</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Warkentin TE. Autoimmune Heparin-Induced Thrombocytopenia. J Clin Med. 2023;12(21):6921. https://doi.org/10.3390/jcm12216921</mixed-citation><mixed-citation xml:lang="en">Warkentin TE. Autoimmune Heparin-Induced Thrombocytopenia. J Clin Med. 2023;12(21):6921. https://doi.org/10.3390/jcm12216921</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Elberry MH, Abdelgawad HAH, Hamdallah A, Abdella WS, Ahmed AS, Ghaith HS, et al. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines. J Thromb Thrombolysis. 2022;53(4):798-823. https://doi.org/10.1007/s11239-021-02626-w</mixed-citation><mixed-citation xml:lang="en">Elberry MH, Abdelgawad HAH, Hamdallah A, Abdella WS, Ahmed AS, Ghaith HS, et al. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines. J Thromb Thrombolysis. 2022;53(4):798-823. https://doi.org/10.1007/s11239-021-02626-w</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">D'Agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, et al. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration. J Pers Med. 2021;11(4):285. https://doi.org/10.3390/jpm11040285</mixed-citation><mixed-citation xml:lang="en">D'Agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, et al. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration. J Pers Med. 2021;11(4):285. https://doi.org/10.3390/jpm11040285</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Marietta M, Coluccio V, Luppi M. Potential mechanisms of vaccine-induced thrombosis. Eur J Intern Med. 2022;105:1-7. https://doi.org/10.1016/j.ejim.2022.08.002</mixed-citation><mixed-citation xml:lang="en">Marietta M, Coluccio V, Luppi M. Potential mechanisms of vaccine-induced thrombosis. Eur J Intern Med. 2022;105:1-7. https://doi.org/10.1016/j.ejim.2022.08.002</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Baker AT, Boyd RJ, Sarkar D, Teijeira-Crespo A, Chan CK, Bates E, et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv. 2021;7(49):eabl8213. https://doi.org/10.1126/sciadv.abl8213</mixed-citation><mixed-citation xml:lang="en">Baker AT, Boyd RJ, Sarkar D, Teijeira-Crespo A, Chan CK, Bates E, et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv. 2021;7(49):eabl8213. https://doi.org/10.1126/sciadv.abl8213</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Banoun H. mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues. Int J Mol Sci. 2023;24(13):10514. https://doi.org/10.3390/ijms241310514</mixed-citation><mixed-citation xml:lang="en">Banoun H. mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues. Int J Mol Sci. 2023;24(13):10514. https://doi.org/10.3390/ijms241310514</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci. 2004;61(21):2738-43. https://doi.org/10.1007/s00018-004-4242-5</mixed-citation><mixed-citation xml:lang="en">Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci. 2004;61(21):2738-43. https://doi.org/10.1007/s00018-004-4242-5</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9. https://doi.org/10.1038%2Fnm1267</mixed-citation><mixed-citation xml:lang="en">Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9. https://doi.org/10.1038%2Fnm1267</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28(7):542-54. https://doi.org/10.1016/j.molmed.2022.04.007</mixed-citation><mixed-citation xml:lang="en">Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28(7):542-54. https://doi.org/10.1016/j.molmed.2022.04.007</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal S, Perincheri S, Fleming T, Poulson C, Tiffany B, Bremner RM, et al. Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. J Immunol. 2021;207(10):2405-10. https://doi.org/10.4049%2Fjimmunol.2100637</mixed-citation><mixed-citation xml:lang="en">Bansal S, Perincheri S, Fleming T, Poulson C, Tiffany B, Bremner RM, et al. Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. J Immunol. 2021;207(10):2405-10. https://doi.org/10.4049%2Fjimmunol.2100637</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Krauson AJ, Casimero FVC, Siddiquee Z, Stone JR. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines. 2023;8(1):141. https://doi.org/10.1038/s41541-023-00742-7</mixed-citation><mixed-citation xml:lang="en">Krauson AJ, Casimero FVC, Siddiquee Z, Stone JR. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines. 2023;8(1):141. https://doi.org/10.1038/s41541-023-00742-7</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Sano H, Kase M, Aoyama Y, Sano S. A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis. J Dermatol. 2023;50(9):1208-12. https://doi.org/10.1111/1346-8138.16816</mixed-citation><mixed-citation xml:lang="en">Sano H, Kase M, Aoyama Y, Sano S. A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis. J Dermatol. 2023;50(9):1208-12. https://doi.org/10.1111/1346-8138.16816</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, McGary H, Razmpour R, Galie PA, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier. bioRxiv [Preprint]. 2020:2020.06.15.150912. https://doi.org/10.1101/2020.06.15.150912</mixed-citation><mixed-citation xml:lang="en">Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, McGary H, Razmpour R, Galie PA, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier. bioRxiv [Preprint]. 2020:2020.06.15.150912. https://doi.org/10.1101/2020.06.15.150912</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Theoharides TC, Kempuraj D. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. Cells. 2023;12(5):688. https://doi.org/10.3390/cells12050688</mixed-citation><mixed-citation xml:lang="en">Theoharides TC, Kempuraj D. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. Cells. 2023;12(5):688. https://doi.org/10.3390/cells12050688</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Navarra A, Albani E, Castellano S, Arruzzolo L, Levi-Setti PE. Coronavirus Disease-19 Infection: Implications on Male Fertility and Reproduction. Front Physiol. 2020;11:574761. https://www.doi.org/10.3389/fphys.2020.574761</mixed-citation><mixed-citation xml:lang="en">Navarra A, Albani E, Castellano S, Arruzzolo L, Levi-Setti PE. Coronavirus Disease-19 Infection: Implications on Male Fertility and Reproduction. Front Physiol. 2020;11:574761. https://www.doi.org/10.3389/fphys.2020.574761</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Edelman A, Boniface ER, Male V, Cameron ST, Benhar E, Han L, et al. Association between menstrual cycle length and Covid-19 vaccination: global, retrospective cohort study of prospectively collected data. BMJ Med. 2022;1(1):e000297. https://doi.org/10.1136/bmjmed-2022-000297</mixed-citation><mixed-citation xml:lang="en">Edelman A, Boniface ER, Male V, Cameron ST, Benhar E, Han L, et al. Association between menstrual cycle length and Covid-19 vaccination: global, retrospective cohort study of prospectively collected data. BMJ Med. 2022;1(1):e000297. https://doi.org/10.1136/bmjmed-2022-000297</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Lessans N, Rottenstreich A, Stern S, Gilan A, Saar TD, Porat S, et al. The effect of BNT162b2 SARS-CoV-2 mRNA vaccine on menstrual cycle symptoms in healthy women. Int J Gynaecol Obstet. 2023;160(1):313-8. https://doi.org/10.1002/ijgo.14356</mixed-citation><mixed-citation xml:lang="en">Lessans N, Rottenstreich A, Stern S, Gilan A, Saar TD, Porat S, et al. The effect of BNT162b2 SARS-CoV-2 mRNA vaccine on menstrual cycle symptoms in healthy women. Int J Gynaecol Obstet. 2023;160(1):313-8. https://doi.org/10.1002/ijgo.14356</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Weickenmeier J, Jucker M, Goriely A, Kuhl E. A Physics-based Model Explains the Prion-like Features of Neurodegeneration in Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. J of the Mechanics and Physics of Solids. 2019;124:264-81. https://doi.org/10.1016/j.jmps.2018.10.013</mixed-citation><mixed-citation xml:lang="en">Weickenmeier J, Jucker M, Goriely A, Kuhl E. A Physics-based Model Explains the Prion-like Features of Neurodegeneration in Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. J of the Mechanics and Physics of Solids. 2019;124:264-81. https://doi.org/10.1016/j.jmps.2018.10.013</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693-714. https://doi.org/10.1016/j.cell.2022.12.032</mixed-citation><mixed-citation xml:lang="en">Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693-714. https://doi.org/10.1016/j.cell.2022.12.032</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Kuvandık A, Özcan E, Karaduman S, Sungurtekin H. Creutzfeldt-Jakob Disease After the Coronavirus Disease-2019 Vaccination. Turk J Intensive Care. 2022;20:61-4. https://doi.org/10.4274/tybd.galenos.2021.91885</mixed-citation><mixed-citation xml:lang="en">Kuvandık A, Özcan E, Karaduman S, Sungurtekin H. Creutzfeldt-Jakob Disease After the Coronavirus Disease-2019 Vaccination. Turk J Intensive Care. 2022;20:61-4. https://doi.org/10.4274/tybd.galenos.2021.91885</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Na DL, Suh CK, Choi SH, Moon HS, Seo DW, Kim SE, et al. Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol. 1999;56(8):951-7. https://doi.org/10.1001/archneur.56.8.951</mixed-citation><mixed-citation xml:lang="en">Na DL, Suh CK, Choi SH, Moon HS, Seo DW, Kim SE, et al. Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol. 1999;56(8):951-7. https://doi.org/10.1001/archneur.56.8.951</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-34. https://doi.org/10.1093/oxfordjournals.aje.a120955</mixed-citation><mixed-citation xml:lang="en">Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-34. https://doi.org/10.1093/oxfordjournals.aje.a120955</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Aldén M, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr Issues Mol Biol. 2022;44(3):1115-26. https://doi.org/10.3390/cimb44030073</mixed-citation><mixed-citation xml:lang="en">Aldén M, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr Issues Mol Biol. 2022;44(3):1115-26. https://doi.org/10.3390/cimb44030073</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Afshar MZ, Pirzaman TA, Liang JJ, Sharma A, Pirzadeh M, Babazadeh A, et al. Do we miss rare adverse events induced by COVID-19 vaccination? Front Med (Lausanne). 2022;9:933914. https://doi.org/10.3389/fmed.2022.933914</mixed-citation><mixed-citation xml:lang="en">Afshar MZ, Pirzaman TA, Liang JJ, Sharma A, Pirzadeh M, Babazadeh A, et al. Do we miss rare adverse events induced by COVID-19 vaccination? Front Med (Lausanne). 2022;9:933914. https://doi.org/10.3389/fmed.2022.933914</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Goldman S, Bron D, Tousseyn T, Vierasu I, Dewispelaere L, Heimann P, et al. Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report. Front Med (Lausanne). 2021;8:798095. https://pmc.ncbi.nlm.nih.gov/articles/PMC8846585/</mixed-citation><mixed-citation xml:lang="en">Goldman S, Bron D, Tousseyn T, Vierasu I, Dewispelaere L, Heimann P, et al. Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report. Front Med (Lausanne). 2021;8:798095. https://pmc.ncbi.nlm.nih.gov/articles/PMC8846585/</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Mizutani M, Mitsui H, Amano T, Ogawa Y, Deguchi N, Shimada S, et al. Two cases of axillary lymphadenopathy diagnosed as diffuse large B-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2022;36(8):e613-e615. https://doi.org/10.1111/jdv.18136</mixed-citation><mixed-citation xml:lang="en">Mizutani M, Mitsui H, Amano T, Ogawa Y, Deguchi N, Shimada S, et al. Two cases of axillary lymphadenopathy diagnosed as diffuse large B-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2022;36(8):e613-e615. https://doi.org/10.1111/jdv.18136</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Cavanna L, Grassi SO, Ruffini L, Michieletti E, Carella E, Palli D, et al. Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature. Medicina (Kaunas). 2023;59(1):157. https://doi.org/10.3390/medicina59010157</mixed-citation><mixed-citation xml:lang="en">Cavanna L, Grassi SO, Ruffini L, Michieletti E, Carella E, Palli D, et al. Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature. Medicina (Kaunas). 2023;59(1):157. https://doi.org/10.3390/medicina59010157</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Kyriakopoulos AM, Nigh G, McCullough PA, Olivier MD, Seneff S. Bell's palsy or an aggressive infiltrating basaloid carcinoma post-mRNA vaccination for COVID-19? A case report and review of the literature. EXCLI J. 2023;22:992-1011. https://dx.doi.org/10.17179/excli2023-6145</mixed-citation><mixed-citation xml:lang="en">Kyriakopoulos AM, Nigh G, McCullough PA, Olivier MD, Seneff S. Bell's palsy or an aggressive infiltrating basaloid carcinoma post-mRNA vaccination for COVID-19? A case report and review of the literature. EXCLI J. 2023;22:992-1011. https://dx.doi.org/10.17179/excli2023-6145</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">De la Torre-Gomar FJ, Llamas-Molina JM, Pegalajar-García MD, Pérez-Valencia C, Carrero-Castaño A, Ruiz-Villaverde R. Primary Cutaneous CD4 Small/Medium T-Cell Lymphoproliferative Disorder Following COVID-19 Vaccination-What Do We Know about Lymphoproliferative Disorders and Cutaneous Lymphomas after COVID-19 Vaccination? A Report of an Atypical Case and a Review of the Literature. Life (Basel). 2024;14(3):386. https://doi.org/10.3390/life14030386</mixed-citation><mixed-citation xml:lang="en">De la Torre-Gomar FJ, Llamas-Molina JM, Pegalajar-García MD, Pérez-Valencia C, Carrero-Castaño A, Ruiz-Villaverde R. Primary Cutaneous CD4 Small/Medium T-Cell Lymphoproliferative Disorder Following COVID-19 Vaccination-What Do We Know about Lymphoproliferative Disorders and Cutaneous Lymphomas after COVID-19 Vaccination? A Report of an Atypical Case and a Review of the Literature. Life (Basel). 2024;14(3):386. https://doi.org/10.3390/life14030386</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Okoro EO, Ikoba NA, Okoro BE, Akpila AS, Salihu MO. Paradoxical increase in global COVID-19 deaths with vaccination coverage: World Health Organization estimates (2020–2023). International Journal of Risk &amp; Safety in Medicine. 2025;0(0). https://doi.org/10.1177/09246479251336610</mixed-citation><mixed-citation xml:lang="en">Okoro EO, Ikoba NA, Okoro BE, Akpila AS, Salihu MO. Paradoxical increase in global COVID-19 deaths with vaccination coverage: World Health Organization estimates (2020–2023). International Journal of Risk &amp; Safety in Medicine. 2025;0(0). https://doi.org/10.1177/09246479251336610</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Marcello E, Chiono V. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting. Int J Mol Sci. 2023;24(4):3390. https://doi.org/10.3390/ijms24043390</mixed-citation><mixed-citation xml:lang="en">Marcello E, Chiono V. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting. Int J Mol Sci. 2023;24(4):3390. https://doi.org/10.3390/ijms24043390</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell. 2021;184(17):4380-91.e14. https://doi.org/10.1016/j.cell.2021.06.008</mixed-citation><mixed-citation xml:lang="en">Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell. 2021;184(17):4380-91.e14. https://doi.org/10.1016/j.cell.2021.06.008</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Alfonso P, Butković A, Fernández R, Riesgo A, Elena SF. Unveiling the hidden viromes across the animal tree of life: insights from a taxonomic classification pipeline applied to invertebrates of 31 metazoan phyla. mSystems. 2024;9(5):e0012424. https://doi.org/10.1128/msystems.00124-24</mixed-citation><mixed-citation xml:lang="en">Alfonso P, Butković A, Fernández R, Riesgo A, Elena SF. Unveiling the hidden viromes across the animal tree of life: insights from a taxonomic classification pipeline applied to invertebrates of 31 metazoan phyla. mSystems. 2024;9(5):e0012424. https://doi.org/10.1128/msystems.00124-24</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
